Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

tibody with a drug-loaded nano-particle.
  • AmiKet™ -  a prescription topical analgesic cream designed to provide long-term relief from the pain of peripheral neuropathies, which affects more than 15 million people in the U.S.  IPI will continue EpiCept's efforts to out license the product candidate for Phase III development and commercial marketing for the treatment of chemotherapy-induced peripheral neuropathic pain (CIPN) and possibly other peripheral neuropathies.  AmiKet has obtained Fast Track status for the treatment of CIPN and is eligible for an FDA Special Protocol Assessment.  AmiKet has also been granted orphan drug status for the treatment of post-herpetic neuralgia.
  • Crolibulin -  a vascular disruption agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.  In December 2010 the National Cancer Institute initiated a Phase Ib/II trial for crolibulin to assess safety and efficacy in combination with cisplatin in patients with anaplastic thyroid cancer.  The Phase I safety portion of the trial completed in early 2013, and the results were presented at the May 2013 ASCO meeting in Chicago.  Immune believes that crolibulin may be a candidate for use with its NanomAb technology.
  • IPI will have dual headquarters in Herzliya-Pituach, Israel and in the New York City area, with research laboratories in Rehovot, Israel.  Daniel Teper, PharmD, Chief Executive Officer of Immune Pharmaceuticals Ltd., will be IPI's Chairman and CEO.  Dr. David Sidransky, Director of Head and Neck Research Division, Professor of Oncology at the Johns Hopkins School of Medicine, and a former Vice Chairman of the Board of Directors of ImClone Systems, will be the Vice Chairman of the Board.  The board of directors of the combined company will consist of Dr. Daniel Teper, Dr. David Sidransky, the remainder of the current board of directors of Immune, which co
    '/>"/>

    SOURCE EpiCept Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    6. Pharmasset Reports Fiscal Year End 2011 Financial Results
    7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
    (Date:1/15/2014)... 2014 Cynvenio, a cancer diagnostics company ... genomic analysis of tumor cells in the bloodstream, today ... cancer decision support application powered by CollabRx, Inc. ... genomic test, Therapy Finder will provide breast cancer patients ...
    (Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
    (Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
    Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
    ... Licensing Opportunities , , ... KANSAS CITY, Mo. , May 17 ... Inc., today announced that it is continuing its strategic international expansion ... group of leading research hospitals and institutes based in Toronto, ...
    ... , May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris ... drug development company specialized in oncology and endocrinology, today ... orphan medicinal product designation from the Committee for Orphan ... its compound AEZS-108 for the treatment of ovarian cancer. ...
    ... China, May 17 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: ... of a leading over-the-counter Hepatitis B medicine, Xin,Aoxing Oleanolic Acid ... financial results of the first quarter ended March,31, 2010 ... increased 66.0% to $12.4 million, -- Q1 ...
    Cached Biology Technology:The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 2The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 3Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 2Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 2Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 4Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 5Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 6Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 7Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 8Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 9Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 10Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 11Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 12Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 13
    (Date:4/22/2014)... of Montana,s Wildlife Biology Program, co-wrote a research paper published ... of Sciences on how streamwater chemistry varies across a ... Lowe and co-authors from ... the Cary Institute of Ecosystem Studies, the University of Connecticut ... water samples collected every 10 meters along 32 tributaries of ...
    (Date:4/22/2014)... HOUSTON (April 22, 2014) Biotechnology scientists must ... for new patent and licensing guidelines, according to a ... Policy. , Published in the current issue of the ... on the June 2013 U.S. Supreme Court ruling in ... Genetics that naturally occurring genes are unpatentable. The court ...
    (Date:4/22/2014)... nanotechnology expert will present a poster titled ... 7th International Nanotoxicology Congress to be held ... Monita Sharma will outline a strategy consistent with the ... " Toxicity Testing in the 21st Century: A Vision ... methods involving human cells and cell lines for mechanistic ...
    Breaking Biology News(10 mins):New research focuses on streamwater chemistry, landscape variation 2New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
    ... adults with the blood cancer mixed-lineage leukemia (MLL) typically have ... birthdays. Although there are varying causes of MLL, most cases ... and the AF4 genes. When the ... cancer-causing oncogene is created. Although researchers have known that the ...
    ... engineering holds great promise for the treatment of conditions ... injuries. However, bone and cartilage currently produced in ... the body so they,re not clinically viable. Dr. ... of Medicine & Dentistry at The University of Western ...
    ... 2008 -- A rat thought extinct for 11 million years ... new species discovered in the Greater Mekong Region of Southeast ... launched by World Wildlife Fund (WWF). First ... discovered or newly identified by science between 1997 and 2007 ...
    Cached Biology News:Tracking the molecular pathway to mixed-lineage leukemia 2Building better bones and tissue in the lab 2Over 1,000 species discovered in the Greater Mekong in past decade 2
    ... a user-friendly statistical software package for scientists ... statistical analysis without being a statistical expert.Just ... and research and SigmaStat suggests the appropriate ... tests underlying assumptions and suggests another test ...
    ... Novexin offers bespoke, cost-effective solutions for complex protein ... extensive expertise and experience to help you develop a ... , , ... , transfer all methodology ...
    ... is a chemiluminescent signal enhancing reagent ... boost the signal obtained with all ... ChemiLucent™ Plus is derived from a ... complex- or chemiluminescent substrate enhancers, ChemiLucent™ ...
    ... GeneSpring Workgroup solution is a highly ... mining expression data in a workgroup ... deployed in over 40 leading pharmaceutical, ... worldwide. GeneSpring Workgroup streamlines genomics research ...
    Biology Products: